Indeed, local administration of the OPRL1 antagonist SB612111 (3 mM) to tumor-bearing mice (both flank and hind paw models) accelerated tumor growth and increased tumor weight by PID 13 (Fig. 6A–C, SF. Here, OPRL1 is linked to neoplasm.